3,938
Views
2
CrossRef citations to date
0
Altmetric
Article

Topical prebiotics/postbiotics and PRURISCORE validation in atopic dermatitis. International study of 396 patients

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , & show all
Article: 2131703 | Received 18 Jun 2022, Accepted 24 Aug 2022, Published online: 17 Oct 2022

References

  • David Boothe W, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. Adv Exp Med Biol. 2017;1027:21–37.
  • Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136–1143.
  • Ali F, Vyas J, Finlay AY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol. 2020;100(12):adv00161.
  • Beck LA, Thaçi D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020;21(4):567–577.
  • Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–1293.
  • Fishbein AB, Silverberg JI, Wilson EJ, et al. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020;8(1):91–101.
  • Grimalt R, Mengeaud V, Cambazard F. Study investigators’ group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007;214(1):61–67.
  • Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734.
  • AA.VV. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European task force on atopic dermatitis. Dermatology. 1993;186(1):23–31.
  • Langley RG, Feldman SR, Nyirady J, et al. The 5-point investigator’s global assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat. 2015;26(1):23–31.
  • Finlay AY, Khan GK. Dermatology life quality index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.
  • Lewis-Jones MS, Finlay AY. The children’s dermatology life quality index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942–949.
  • Basra MK, Gada V, Ungaro S, et al. Infants’ dermatitis quality of life index: a decade of experience of validation and clinical application. Br J Dermatol. 2013;169(4):760–768.
  • Williams HC, Chalmers J. Prevention of atopic dermatitis. Acta Derm Venereol. 2020;100(12):adv00166.
  • Giua C, Floris NP, Schlich M, et al. Dermatitis in community pharmacies: a survey on Italian pharmacists’ management and implications on corticophobia. PHAR. 2021;68(3):671–677.
  • Trikamjee T, Comberiati P, D’Auria E, et al. Nutritional factors in the prevention of atopic dermatitis in children. Front Pediatr. 2021;8:577413.
  • Jeong K, Kim M, Jeon SA, et al. Randomized trial of Lactobacillus rhamnosus IDCC 3201 tyndallizate (RHT3201) for treating atopic dermatitis. Pediatr Allergy Immunol. 2020;31(7):783–792.
  • Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: the international scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491–502.
  • Roberfroid M, Gibson GR, Hoyles L, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104 (Suppl 2):S1–S63.
  • Salminen S, Collado MC, Endo A, et al. The international scientific association of probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18(9):649–667.
  • Tiplica GS, Kaszuba A, Malinauskienė L, et al. Prevention of flares in children with atopic dermatitis with regular use of an emollient containing glycerol and paraffin: a randomized controlled study. Pediatr Dermatol. 2017;34(3):282–289.
  • Lowe AJ, Su JC, Allen KJ, et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. Br J Dermatol. 2018;178(1):e19–e21.
  • van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2(2):CD012119.
  • Skjerven HO, Rehbinder EM, Vettukattil R, et al. Emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet. 2020;395(10228):951–961.
  • Fanfaret IS, Boda D, Ion LM, et al. Probiotics and prebiotics in atopic dermatitis: pros and cons (review). Exp Ther Med. 2021;22(6):1376.
  • Baldwin H, Aguh C, Andriessen A, et al. Atopic dermatitis and the role of the skin microbiome in choosing prevention, treatment, and maintenance options. J Drugs Dermatol. 2020;19(10):935–940.